Three different multiple, oral dose regimens of GPA-748 will safely increase GH IGF-1, and IGF-BP-3 levels in growth hormone deficient adults. The oral growth hormone releasing peptide, GPA-748, was administered to growth hormone deficient adult men and women in a double blind placebo controlled multicenter study to assess the growth hormone stimulating action of this peptide. Patients had a previous history of pituitary disease. This is a multicenter study, the blind has not yet been broken and the results are not yet available for analysis. This study has been completed.
Showing the most recent 10 out of 674 publications